Link Biologics is pioneering the development of protein biologics that harness the protective biology of TSG-6 and set new standards of care via multi-pathway modulation of inflammation, tissue protection and repair. With broad potential across inflammatory and degenerative conditions, the Company’s lead programmes focus on Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD); together these represent multi-billion-dollar global markets with significant unmet needs.


Link Biologics’ approach is validated by its DED programme (LB001), which has a fully funded >£200M partnership with Théa Group. Its Wet AMD programme (LB004), which utilises subcutaneous administration rather than intraocular injections, has been accelerated by leveraging outputs from LB001 alongside robust standalone preclinical data. Both programmes are expected to reach the clinic in 2027 with a clear path to key, value-creating, milestones.


Led by a world-class team with decades of academic and commercial experience in TSG-6 biology and drug development, Link Biologics combines deep scientific and pharma leadership with a collaborative, outcome-driven culture, positioning the Company to deliver game-changing therapies.

Link Biologics

Org chart

Teams

Offices